Q3 2024 Holdings
Filed 2024-11-14 | 36 holdings | $6.9B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| United Therapeutics Corp(UTHR) | Common | 91307C102 | $1.0B | 2,858,888 | 14.9% |
| Ascendis Pharma(ASND) | Sponsored ADR | 04351P101 | $744.9M | 4,988,888 | 10.9% |
| Argenx SE(ARGX) | Sponsored ADR | 04016X101 | $671.3M | 1,238,467 | 9.8% |
| Krystal Biotech Inc(KRYS) | Common | 501147102 | $477.3M | 2,622,222 | 7.0% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $430.6M | 2,029,000 | 6.3% |
| Apellis Pharmaceuticals Inc.(APLS) | Common | 03753U106 | $320.4M | 11,111,111 | 4.7% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $319.2M | 2,555,555 | 4.7% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $315.8M | 6,875,000 | 4.6% |
| Amicus Therapeutics Inc.(FOLD) | Common | 03152W109 | $247.5M | 23,175,000 | 3.6% |
| Intra-Cellular Therapies Inc(ITCIEUR) | Common | 46116X101 | $223.2M | 3,050,000 | 3.3% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $223.1M | 5,666,666 | 3.3% |
| Kymera Therapeutics Inc(KYMR) | Common | 501575104 | $213.0M | 4,500,000 | 3.1% |
| Vera Therapeutics Inc(VERA) | Common | 92337R101 | $190.5M | 4,309,590 | 2.8% |
| Arrowhead Pharmaceuticals Inc.(ARWR) | Common | 04280A100 | $172.2M | 8,888,888 | 2.5% |
| Biomarin Pharmaceutical Inc(BMRN) | Common | 09061G101 | $143.3M | 2,038,015 | 2.1% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $139.7M | 2,770,100 | 2.0% |
| Vaxcyte Inc(PCVX) | Common | 92243G108 | $134.3M | 1,175,000 | 2.0% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $110.1M | 2,181,000 | 1.6% |
| Biocryst Pharmaceuticals Inc(BCRX) | Common | 09058V103 | $90.2M | 11,865,000 | 1.3% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $74.9M | 3,888,437 | 1.1% |
| Ocular Therapeutix Inc(OCUL) | Common | 67576A100 | $70.1M | 8,060,000 | 1.0% |
| Kura Oncology Inc(KURA) | Common | 50127T109 | $69.2M | 3,541,505 | 1.0% |
| Merus N V | Common | N5749R100 | $67.7M | 1,355,000 | 1.0% |
| Tourmaline BIO Inc(TRML) | Common | 89157D105 | $57.1M | 2,222,222 | 0.8% |
| Mannkind Corp(MNKD) | Common | 56400P706 | $55.0M | 8,750,000 | 0.8% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $46.1M | 830,000 | 0.7% |
| Autolus Therapeutics PLC(AUTL) | Sponsored ADR | 05280R100 | $44.8M | 12,345,678 | 0.7% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $39.8M | 4,240,000 | 0.6% |
| Taysha Gene Therapies Inc(TSHA) | Common | 877619106 | $37.5M | 18,650,000 | 0.5% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $30.7M | 5,790,236 | 0.4% |
| CG Oncology Inc(CGON) | Common | 156944100 | $26.4M | 700,000 | 0.4% |
| Dyne Therapeutics Inc.(DYN) | Common | 26818M108 | $23.3M | 650,000 | 0.3% |
| Spyre Therapeutics Inc(SYRE) | Common | 00773J202 | $17.6M | 598,600 | 0.3% |
| Aadi Biosciences Inc(WHWK) | Common | 00032Q104 | $5.9M | 2,849,402 | 0.1% |
| Neurogene Inc(NGNE) | Common | 64135M105 | $924.3K | 22,029 | 0.0% |
| Insmed IncPut | Common | 457669957 | $125.0K | 50,000 | 0.0% |